Business events organiser and publisher UBM is hooking up with Belgian-French publishing and printing firm Roularta Media to form a medical print journal joint venture.
UBM Medica and Roularta have merged their respective Belgian professional medical print businesses into ActuaMedica, a 50:50 joint venture company.
The staff and assets relating to UBM Medica's print and digital titles will be combined, as will the prescription pads business of both companies. The joint venture company will retain the rights to publish the Medex directory under licence. ActuaMedica will have its headquarters in Roularta's offices in Brussels.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
UBM stressed it remains committed to the Belgium medical market through its continued 100% ownership of its digital data businesses in Belgium (Medibridge and drug information systems), as well as its
50% equity interest in ActuaMedica.
"ActuaMedica is well placed to prosper in both print and digital as the media market evolves. In parallel we will continue to to build our wholly-owned Belgian data business as part of our UBM Medica EMEA [Europe, Middle East and Africa] operations," said Henry Elkington, Chief Executive Officer of UBM Medica.
jh
-
What happens if you can’t pay your tax bill, and what is "Time to Pay"?Millions are due to file their tax return this Friday as the self-assessment deadline closes. Though the nightmare is not over until you pay the taxman what you owe - or face a penalty. But what happens if you can't afford to pay HMRC your tax bill, and what is "Time to Pay"?
-
What does Rachel Reeves’s plan for growth mean for UK investors?Rachel Reeves says she is going “further and faster” to kickstart the UK economy, but investors are unlikely to be persuaded
